Grants per year
Personal profile
Research Interests
Myeloma, Transplantation
Certifications and Licenses
| Internal Medicine |
Training Experience
| 1991 | Residency, Bombay University, India |
| 1992 | Fellowship, Hadassah University Hospital, Israel |
Education/Academic qualification
MD, Medicine, University of Mumbai
… → 1991
Research interests keywords
- Amyloidosis
- Monoclonal Antibodies
- Multiple Myeloma
- Plasma Cell Disorders
- Stem Cell Transplant
- Waldenstroms
Fingerprint
Dive into the research topics where Seema Singhal is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #NEOD001-CL002: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis
Covance Inc., Prothena Therapeutics Limited
12/11/15 → 12/11/18
Project: Research project
-
Prot #54767414MMY3010: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to
Janssen Research & Development, LLC
10/23/15 → 10/23/18
Project: Research project
-
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry
Du, Z., Weinhold, N., Song, G. C., Rand, K. A., Van Den Berg, D. J., Hwang, A. E., Sheng, X., Hom, V., Ailawadhi, S., Nooka, A. K., Singhal, S., Pawlish, K., Peters, E. S., Bock, C., Mohrbacher, A., Stram, A., Berndt, S. I., Blot, W. J., Casey, G., Stevens, V. L., & 50 others, Jan 14 2020, In: Blood Advances. 4, 1, p. 181-190 10 p.Research output: Contribution to journal › Article › peer-review
Open Access11 Scopus citations -
Variability in cytogenetic testing for multiple myeloma: a comprehensive analysis from across the United States
Yu, Y., Wade, N. B., Hwang, A. E., Nooka, A. K., Fiala, M. A., Mohrbacher, A., Peters, E. S., Pawlish, K., Bock, C., van Den, D. J., Rand, K. A., Stram, D., Conti, D. V., Auclair, D., Colditz, G. A., Mehta, J., Haiman, C. A., Terebelo, H., Janakiraman, N., Singhal, S., & 9 others, Oct 1 2020, In: JCO Oncology Practice. 16, 10, p. E1169-E1180Research output: Contribution to journal › Article › peer-review
5 Scopus citations -
Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines
Kumar, S. K., Callander, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C., Efebera, Y., Faiman, M., Garfall, A., Godby, K., Holmberg, L., Htut, M., Huff, C. A., Kang, Y., Landgren, O., Malek, E., & 11 others, 2019, In: JNCCN Journal of the National Comprehensive Cancer Network. 17, 10, p. 1154-1165 12 p.Research output: Contribution to journal › Review article › peer-review
Open Access94 Scopus citations -
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
KEYNOTE-183 Investigators, Sep 2019, In: The Lancet Haematology. 6, 9, p. e459-e469Research output: Contribution to journal › Article › peer-review
150 Scopus citations -
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
Stewart, A. K., Krishnan, A. Y., Singhal, S., Boccia, R. V., Patel, M. R., Niesvizky, R., Chanan-Khan, A. A., Ailawadhi, S., Brumm, J., Mundt, K. E., Hong, K., McBride, J., Shon-Nguyen, Q., Xiao, Y., Ramakrishnan, V., Polson, A. G., Samineni, D., Leipold, D., Humke, E. W., McClellan, J. S., & 1 others, Feb 1 2019, In: Blood cancer journal. 9, 2, 17.Research output: Contribution to journal › Article › peer-review
Open Access31 Scopus citations